NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)
ID: 351266Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351266

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-066.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44). This initiative aims to support small business concerns proposing early-stage clinical trials focused on screening, diagnosing, preventing, or treating vision disorders, with an emphasis on trials that typically fall under Phase I or II. The program is crucial for advancing research in vision health and ensuring rigorous scientific and safety standards, with a total funding limit of $2 million available over three years. Applications are open from December 1, 2023, until January 8, 2027, and interested applicants are encouraged to consult with NEI program staff prior to submission. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-066-Full-Announcement.html
    PAR-24-066.html
    The National Eye Institute (NEI), part of the Department of Health and Human Services, has announced a funding opportunity for Small Business Innovation Research (SBIR) Cooperative Agreements to support early-stage clinical trials with greater than minimal risk (U44). This initiative focuses on small business concerns proposing trials aimed at screening, diagnosing, preventing, or treating vision disorders. Key details include a funding limit of $2 million total costs over three years, with applications open from December 1, 2023, through January 8, 2027. Eligible applicants are U.S.-based small businesses that meet specific regulatory criteria, including being predominantly owned by U.S. citizens or permanent residents. The review process will prioritize proposals based on the significance of the problem addressed, the investigators' qualifications, and innovative approaches. The NEI encourages early consultation with program staff and the establishment of data monitoring committees for oversight during trials. Overall, the program aims to advance research in vision health through strategic partnerships with small businesses, ensuring rigorous scientific and safety standards.
    Similar Opportunities
    NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Eye Institute (NEI) for cooperative agreements (U01) aimed at supporting early-stage clinical trials that involve greater than minimal risk, specifically targeting interventions for vision disorders. This initiative encourages applications for Phase I or II trials that are backed by strong preliminary data and require compliance with NIH guidelines, including the establishment of a Data Monitoring and Safety Committee (DSMC) for safety oversight. The funding is crucial for advancing research in the screening, diagnosis, prevention, and treatment of vision disorders, with project budgets reflecting actual needs and a maximum project period of five years. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with the application deadline set for May 7, 2025.
    NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) aimed at accelerating the translation of innovative laboratory research into therapeutic interventions for visual system diseases. This program employs a bi-phasic, milestone-driven mechanism consisting of an Exploratory (R61) phase lasting up to two years and a Developmental (R33) phase lasting up to three years, focusing on generating preclinical data that supports applications for Investigational New Drug (IND) or Investigational Device Exemption (IDE) submissions to the FDA. The initiative is designed to engage diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to foster collaborative efforts in ocular research, ultimately improving health outcomes through vision research. Interested applicants can find more information and guidelines at the provided link, with a funding ceiling of $500,000 and a submission deadline of March 16, 2025.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Collaborative Clinical Vision Research Project, specifically for Resource Center Grants (UG1 Clinical Trial Required). This initiative aims to support large-scale clinical trials focused on screening, diagnosing, preventing, or treating vision disorders, with a particular emphasis on evaluating complex interventions and providing essential services for multi-center trials. The NEI seeks to advance vision health through rigorous research, and applications are encouraged from a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties must submit their applications by May 25, 2026, and can find additional information and guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Clinical Research Study Planning Grant Program (R34), aimed at supporting the development of clinical trial protocols and procedures specifically for eye and vision-related studies. This grant facilitates the preparation of a comprehensive Manual of Procedures (MOP) and allows for preliminary studies to assess recruitment potential, without generating data on intervention effects. Grants may provide up to $150,000 per year for a maximum of two years, with applications due by May 7, 2025. Eligible applicants include a wide range of institutions, including educational, nonprofit, and government entities, and inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NEI Collaborative Clinical Vision Research Project, specifically seeking applications for a Coordinating Center grant under the UG1 activity code. This initiative aims to support large-scale, investigator-initiated clinical trials focused on vision disorders, including interventions for screening, diagnosing, preventing, or treating these conditions, with an emphasis on projects that require significant oversight and management. The NEI's mission is to advance vision research and enhance public health through rigorous clinical trials, ensuring compliance with NIH policies and ethical standards in research involving human subjects. Interested applicants, including a diverse range of organizations such as higher education institutions and nonprofits, must submit their applications by May 25, 2026, and can find further details at the provided NIH grants information email: grantsinfo@nih.gov.
    NEI Collaborative Clinical Vision Research: Chair's Grant (UG1-Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Eye Institute (NEI), has announced a Notice of Funding Opportunity (NOFO) for the NEI Collaborative Clinical Vision Research: Chair's Grant (UG1), aimed at supporting large-scale clinical trials focused on vision disorders. This funding opportunity is intended for projects that evaluate interventions for screening, diagnosing, preventing, or treating vision disorders, specifically requiring a clinical trial with a clear scientific rationale and detailed study design. The NEI emphasizes the importance of these trials in advancing vision science and public health, with awards structured as cooperative agreements to ensure substantial NIH involvement in the research process. Interested applicants must submit their proposals by May 25, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NEI Translational Research Program for Therapeutics, aimed at accelerating the translation of innovative laboratory research into therapeutics for visual system diseases. This program seeks to fund multidisciplinary teams that can generate preclinical data leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications, with a focus on developing biological, pharmacological, and medical device interventions. The initiative underscores the federal commitment to translating biomedical research into practical therapies, ultimately enhancing patient care in ocular health. Grants of up to $1 million per year are available, with applications due by March 16, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.